Table I.

Characteristics of the prostate cancer patients with gene expression data included in the Mayo Clinic training and testing datasets

	Training Dataset							Testing Dataset
	No recurrence			Metastatic-lethal				No recurrence			Metastatic-lethal
	n = 157			n = 212				n = 110			n = 76
	No.	%	Mean (SD)	No.	%	Mean (SD)	P-valuea	No.	%	Mean (SD)	No.	%	Mean (SD)	P-valuea
Age at diagnosis (years)			64.9 (6.6)			65.4 (6.4)	0.5			64.0 (7.2)			62.7 (7.8)	0.3
CAPRA-S score			4.3 (3.0)			6.6 (3.1)	<0.01			5.1 (2.0)			7.0 (2.3)	<0.01
Gleason score
≤ 6	28	17.8		6	2.8		<0.01	12	10.9		0	0		<0.01
7	95	60.5		76	35.8			58	52.7		21	42.1
8–10	34	21.7		130	61.3			40	36.4		44	57.9
Pathologic stageb
Local	83	52.9		58	27.4		<0.01	61	55.5		16	21.1		<0.01
Regional	74	47.1		154	72.6			49	44.5		60	78.9
PSA (ng/mL) at diagnosis
< 4.0	17	10.8		21	9.9		0.03	5	4.5		7	9.2		0.2
4.0–9.9	79	50.3		80	37.8			62	56.4		31	40.8
10.0–19.9	31	19.7		44	20.8			25	22.7		21	27.6
≥ 20	26	16.6		60	28.3			18	16.4		17	22.4

^aBased on a t-test (age), chi-square or Fisher’s exact test (categorical variables).

^bLocal stage = pT2, N0/NX, M0; regional stage = pT3/T4 and/or N1, M0.